Arginine methyltransferase inhibitor 1 exhibits antitumor effects against cervical cancer in vitro and in vivo.
Pharmazie
; 73(5): 269-273, 2018 05 01.
Article
en En
| MEDLINE
| ID: mdl-29724292
ABSTRACT
Protein arginine methyltransferase 5 (PRMT5), a type II PRMT, is highly expressed in several types of tumors including cervical cancer. Arginine methyltransferase inhibitor 1 (AMI-1) inhibits solid tumors by targeting PRMT5. However, the effect of AMI-1 on cervical cancer is still unknown. In this study, we provided the first evidence that AMI-1 reduced cervical cancer cell proliferation, colony formation and promoted cell apoptosis in vitro. Suppression of tumorigenicity was also confirmed in vivo. Mechanistic studies revealed that AMI-1 significantly reduced PRMT5 level in cells and mice xenografts model of cervical cancer. These results suggest that AMI-1 inhibits cervical cancer by type II PRMT5.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Proteína-Arginina N-Metiltransferasas
/
Urea
/
Neoplasias del Cuello Uterino
/
Naftalenosulfonatos
/
Antineoplásicos
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Pharmazie
Asunto de la revista:
FARMACIA
Año:
2018
Tipo del documento:
Article